Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled 1, Frizzled 2 or Frizzled 7 extracellular cysteine-rich domain
AssigneeKyowa Kirin Co., Ltd.
InventorsMakoto Kakitani, Kazuma Tomizuka
Life of this patent
Estimating the term…
Abstract
This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
Claims12
A method for increasing bone mass, bone density and/or bone strength, comprising:
- administering to a mammalian animal with a disease selected from the group consisting of osteoporosis, osteoarthritis, articular rheumatism, hypercalcemia, Paget's disease of bone, osteopetrosis, Camurati-engelmann's disease, arthropathy, primary hyperthyreosis, osteopenia, osteohalisteresis, rachitis, traumatic bone fracture, and fatigue bone fracture, an effective amount of a pharmaceutical composition which comprises, as an active ingredient, a protein comprising an extracellular cysteine-rich domain comprising the amino acid sequence of SEQ ID NO:21 or 26, to increase bone mass, bone density and/or bone strength.
Dependencies are inferred from the claim text.